Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis

红斑 医学 皮疹 皮肤病科 水肿 特应性皮炎 外科
作者
Teppei Hagino,Mai Yoshida,Risa Hamada,Eita Fujimoto,Hidehisa Saeki,Naoko Kanda
出处
期刊:Journal of Dermatology [Wiley]
卷期号:50 (12): 1576-1584 被引量:10
标识
DOI:10.1111/1346-8138.16950
摘要

Atopic dermatitis (AD) is a chronic eczematous disease with various types of rash, erythema, edema/papulation, excoriation, or lichenification. Janus kinase 1 inhibitor upadacitinib is effective for moderate-to-severe AD. We aimed to investigate the therapeutic effects of upadacitinib on each rash type in AD patients in real-world clinical practice. Seventy-two Japanese patients with moderate-to-severe AD were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. The Eczema Area and Severity Index (EASI) scores for erythema, edema/papulation, excoriation, or lichenification on the whole body or on head and neck, upper limbs, lower limbs, or trunk were assessed at weeks 0, 4, and 12 of treatment. The proportions of patients who achieved resolution or at least 75% reduction of EASI from baseline (EASI 75) for individual rash types were calculated at weeks 4 and 12 on the whole body or each anatomical site. The resolution rates for excoriation, erythema, edema/papulation, or lichenification on the whole body were 38.3%, 23.7%, 21.7%, and 8.3% at week 4 and 18.3%, 18.6%, 11.6%, and 13.3% at week 12, respectively. The EASI scores for all rash types significantly decreased at weeks 4 and 12 compared to week 0. The achievement rates of EASI 75 for excoriation, erythema, edema/papulation, or lichenification on the whole body were 67.2%, 66.7%, 49.2%, and 37.7% at week 4 and 57.3%, 65%, 41%, and 41% at week 12, respectively. The achievement rate of EASI 75 for erythema on head and neck at week 4 (45.3%) was lower than that on upper limbs (71%) and on lower limbs (70.8%), and that on head and neck at week 12 (42.2%) was lower than that on lower limbs (69.2%). These results indicate that upadacitinib is effective for all AD rash types, especially for excoriation and erythema, while head-and-neck erythema might be less responsive to upadacitinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简奥斯汀完成签到 ,获得积分10
6秒前
五本笔记完成签到 ,获得积分10
6秒前
9秒前
花花发布了新的文献求助20
9秒前
asd113发布了新的文献求助10
13秒前
美满的小蘑菇完成签到 ,获得积分10
13秒前
自然白安完成签到 ,获得积分10
19秒前
量子星尘发布了新的文献求助10
22秒前
等待小鸽子完成签到 ,获得积分10
24秒前
龙虾发票完成签到,获得积分10
31秒前
小康学弟完成签到 ,获得积分10
31秒前
了0完成签到 ,获得积分10
31秒前
慕青应助科研通管家采纳,获得10
34秒前
彭于晏应助科研通管家采纳,获得30
34秒前
毛豆爸爸应助科研通管家采纳,获得20
34秒前
林利芳完成签到 ,获得积分0
35秒前
JaneChen完成签到 ,获得积分10
37秒前
健壮惋清完成签到 ,获得积分10
37秒前
38秒前
gabee完成签到 ,获得积分10
42秒前
liang19640908完成签到 ,获得积分10
45秒前
奋斗的雪曼完成签到 ,获得积分10
51秒前
粗心的飞槐完成签到 ,获得积分10
51秒前
LELE完成签到 ,获得积分10
58秒前
了0完成签到 ,获得积分10
59秒前
apocalypse完成签到 ,获得积分10
1分钟前
guhao完成签到 ,获得积分10
1分钟前
指导灰完成签到 ,获得积分10
1分钟前
善良的火完成签到 ,获得积分10
1分钟前
优雅夕阳完成签到 ,获得积分10
1分钟前
Jasper应助光亮的自行车采纳,获得10
1分钟前
miki完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
糖宝完成签到 ,获得积分10
1分钟前
KX2024完成签到,获得积分10
1分钟前
松松发布了新的文献求助20
1分钟前
nusiew完成签到,获得积分10
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
陶醉的翠霜完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022